News|Podcasts|November 20, 2026

ACT Brief: AI Trial Matching Access, IRB Oncology Expertise, and Livsayis Myasthenia Gravis Approval

In today’s ACT Brief, we examine why AI-enabled trial matching could close the oncology access gap, why IRBs need substantive therapeutic expertise, and how FDA approved Regeneron’s Livsayis, a treatment given four times a year for myasthenia gravis.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In a new Q&A, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, discusses why so many patients from underrepresented groups are never asked to join a clinical trial. He explains how AI-enabled matching and screening can make oncology access more consistent. He also argues that the conversation with the patient must stay human.
  • In a new contributed article, Tiffany Crowell, senior vice president of clinical operations at Acrivon Therapeutics, argues that sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials. She notes that increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist. She also contends that informed consent review requires an understanding of the oncology treatment landscape.
  • FDA approved Regeneron’s Livsayis for adults with antibody-positive generalized myasthenia gravis, the first siRNA therapy approved for the disease. In the Phase III NIMBLE trial across 86 sites, MG-ADL scores improved by 4.5 points at week 24, compared with 2.2 points on placebo. The label carries a boxed warning for serious meningococcal infection, so patients must complete vaccination before the first dose.

That’s all for today’s ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article